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Critical and diverse roles of phosphates in human
bone formation
Erik A. B. Hughes, ab Thomas E. Robinson, a David B. Bassett, ac
Sophie C. Cox a and Liam M. Grover *a
Humans utilise biomineralisation in the formation of bone and teeth. Human biomineralisation processes
are defined by the transformation of an amorphous phosphate-based precursor to highly organised
nanocrystals. Interestingly, ionic phosphate species not only provide a fundamental building block of
biological mineral, but rather exhibit several diverse roles in mediating mineral formation in the physiological
milieu. In this review, we focus on elucidating the complex roles of phosphate ions and molecules within
human biomineralisation pathways, primarily referring to the nucleation and crystallisation of bone mineral.
1. Introduction
Phosphate is essential for terrestrial life. Along with water,
carbon, nitrogen and oxygen, phosphates hold the same funda-
mental importance for the existence of life as we know it. For
example, phosphate is a critical component of our genetic
information. It comprises over 25% of our DNA by mass and
bridges the deoxyribose molecules to maintain the complex
double helix arrangement.1,2 However, the indispensable nature
of phosphate is not limited to our genetic make-up. Physiological
phosphate is present in soft tissues (14%) and extracellular fluid
(1%).3 In soft tissue, intracellular phosphate can be found as part
of not only nucleic acids, but also cell membrane phospholipids,
phosphorylated amino acids (serine, threonine, and tyrosine
in particular) and carbohydrates.4 Therefore, phosphate is a
critically important chemical moiety in all four major classes of
biomacromolecule. Within the extracellular fluid, 10% of phos-
phate is bound to protein, 33% is complexed with calcium or
magnesium and the remainder is unbound.5
Phosphates are also key components in biomineralisation.
Biomineralisation allows for the sophisticated formation of
highly organised, functional and often high-strength tissues
by both vertebrates and invertebrates. In humans, the majority
of phosphate (B85%) is actually present in hard tissues that
form through biomineralisation.5,6 Bones and teeth are prime
examples of exceedingly durable and stiﬀ tissues that exhibit
hierarchical structuring from the nano- to the macro-scale.
Bones provide a supportive framework, facilitate movement
through interaction with muscles and protectively encase our
organs. Less obvious, but equally important functions of bone,
include acid–base and osmotic homeostasis, the storage of
growth factors and the provision of space to generate blood
cells.7 Although the specific mechanisms that dictate biomi-
neralisation are still to be fully understood, it is largely agreed
that such mechanisms are likely to have been conserved
between many species over millennia.8
Our bones consist of a mineralised extracellular matrix,
containing both organic and inorganic components, in addition
to active populations of cells responsible for maintaining a
functional and healthy tissue structure. Organic components
contribute up to 30% of bone by mass. Approximately 90% of
organic matter in hard tissue is accounted for by type-1 collagen,
with non-collagenous proteins (NCPs), lipids and mass of hydration
together making up the remaining 10%.9,10 Up to 70% of the
remaining bone mass primarily consists of a nanocrystalline
calcium phosphate-based mineral, generally described as hydro-
xyapatite ((Ca10(PO4)6(OH)2), HA). This mineral phase was first
identified in bone during the 1920’s by X-ray diﬀraction, which
was later confirmed in the 1930’s.11,12 HA is also the main
mineral constituent of teeth in both enamel and dentine. The
composition of dentine is similar to bone, whereas enamel is
composed of a greater fraction of inorganic mineral (up to 96%).
Enamel is therefore the most extreme example of human
biomineralisation, as well as being the hardest material found
within our bodies.13,14
Given that the formation of mineralised hard tissues in
living systems is governed by a combination of cellularly driven
processes and thermodynamics, biomineralisation should be
considered both biological and chemical in nature. In the case of
humans, phosphates are not only a key building block of biologically
derived mineral, but free phosphates in the biological milieu
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also enact control over the formation of new mineral by influencing
a wide variety of signallingmolecules and enzymes. To this end, this
paper reviews the chemistry and roles of diﬀerent phosphates
within biological microenvironments to better understand the
critical and diverse roles of this versatile chemical moiety in the
context of biomineralisation. The focus is primarily on inorganic
phosphates species, the creation of phosphate-based bone mineral
in addition to briefly touching upon mineral formation under
pathological circumstances.
2. An overview of phosphate
structures
2.1. Orthophosphates
Phosphates are not limited to one single form. Rather they exist
in a range of forms that vary in size, chain length and structural
arrangement. This gives rise to many types of phosphate
molecules and ionic species. Orthophosphate refers to a phosphate
molecule in possession of a single phosphorous atom. In its
simplest form, a phosphorous atom is contained within a
tetrahedron of electronegative oxygen atoms (M3PO4), where
M is an electropositive monovalent ion such as hydrogen or
sodium. Other elements may be present in place of oxygen, for
example sulphur that yields thiophosphate species (PS4xOx
3),
with phosphorous remaining at the tetrahedral core. However, it
is the orthophosphate molecule, and associated ions, composed
of phosphorous, oxygen and hydrogen, that is of importance to
biomineralisation.
Tribasic orthophosphoric acid (H3PO4) serves as a progenitor to
all forms of the orthophosphate anion that can exist in aqueous
physiological environments. Subsequent deprotonation of the
H3PO4 molecule can yield H2PO4
, HPO4
2 and PO4
3 anions
(Fig. 1). This speciation is dependent on the pH and ionic strength,
whereby H3PO4 predominates in strongly acidic conditions,
H2PO4
 predominates in weakly acidic and neutral conditions,
HPO4
2 predominates in weakly basic conditions and PO4
3
predominates in strongly basic conditions.
2.2. Condensed phosphates
Orthophosphate provides the monomer subunit for all phosphate-
based polymers (Fig. 2A), which are also referred to as condensed
phosphates. Condensed phosphates possess P–O–P bonds
between orthophosphate molecules and molecular threads of
P–O–P bonds are classed as polyphosphates (Mn+2PnO3n+1).
Technically the shortest chain polyphosphate is a dimer
Fig. 1 Orthophosphoric acid speciation. Physiological serum concentrations and pKa values of orthophosphate in vivo. The mono- and di-protonated
forms are by far the most common at physiological pH, temperature and salt concentrations, consistent with a pKa value of 7.20.
Fig. 2 Chemical structures of linear and cyclic inorganic phosphate structures with varying chain lengths. (A) Orthophosphate (Pi). (B) Pyrophosphate
(PPi). (C) Inorganic polyphosphate (polyP). (D) Adenosine triphosphate (ATP). (E) Trimetaphosphate (TMP). (F) Hexametaphosphate (HMP).
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consisting of two orthophosphate units, commonly referred
to as pyrophosphate (M4P2O7) (Fig. 2B). Swedish chemist Jo¨ns
Jacob Berzelius was the first to synthesize pyrophosphate
in 1816 by igniting orthophosphoric acid, resulting in its
esterification.15 Biologically, inorganic pyrophosphate (P2O7
4,
PPi) plays an important role in the control of the human
biomineralisation processes (Section 4.1).
Longer polyphosphate chains can consist of several residues,
up to 1  106 orthophosphate monomers (Fig. 2C). Biological
inorganic polyphosphate (polyP) was first discovered in cells in
the late 19th century and is known to be present in both prokaryotes
and eukaryotes. PolyP found in vivo is a linear polymer; however,
large branched polymers can exist. These are termed ultra-
phosphates, though their structure may make them unstable
due to rapid hydrolytic and enzymatic degradation, and as such
they have not been found biologically. The possession of high
energy phosphoanhydride bonds has led to suggestions that
polyP may have a role in the origin of life as both a non-
enzymatically produced energy carrier, as well as an orthophosphate
donor.16,17 Several distinct biological roles of polyP have been
identified in various cell types.18 Whilst this demonstrates the
inter-domain ubiquity of polyP, it makes the exact role of these
phosphate species in the origin of cellular life, and within
specific cellularly influenced processes such as biomineralisation,
diﬃcult to pinpoint.
A polyphosphate chain consisting of three orthophosphate
units is present in the structure of the organophosphate
biomolecule adenosine triphosphate (ATP) (Fig. 2D), which is
released by most cell types, including bone-forming osteoblasts.
Hydrolytic cleavage of the high-energy phosphoanhydride bonds
that link the individual orthophosphate residues together, as
catalysed by phosphatase enzymes, releases the necessary
chemical energy to fuel cellular activities and, by extension, all
of our bodily functions. In addition to its capacity as the
currency of energy in intracellular metabolism, ATP also has
an important role as an extracellular signalling molecule in
biomineralisation, being a source of both orthophosphate and
PPi ions (Sections 4.1 and 4.2).
Although not involved in biological processes, polyphos-
phates can also form symmetrical open or closed ring structures.
These cyclic polyphosphates are better known as metaphosphates
(MnPnO3n) (Fig. 2E and F). Both enzymatic and H
+ and OH
mediated hydrolysis mechanisms are capable of catalysing
the degradation of metaphosphates to orthophosphates and
shorter chains.
3. Orthophosphate and the formation
of bone mineral
3.1. The phosphate required for bone formation
Orthophosphate is an essential building block of biological mineral.
The orthophosphate required for biomineralisation is consumed
through one’s diet, with a typical Western diet correlating to the
provision of between 1000–1600 mg per day, of which 3 mg per kg
bodyweight per day enters the extracellular fluid, exchanging
with bone as required.19 Serum phosphate concentration varies
considerably with age, being greater in infants (1.5–2.65 mM)
and declining toward adulthood (0.8–1.5 mM). This is because
infants require additional levels of phosphate for bone growth
and soft tissue.20,21
In addition to biomineralisation, phosphates are involved in
cell growth, migration, apoptosis, endocytosis and diﬀerentiation,
and as such its presence is tightly regulated by the body.22 The
homeostasis of both phosphate and calcium is governed by a
network of complementary mechanisms interlinking kidney,
intestinal and skeletal function (Fig. 3). The primary regulators
of phosphate within this ‘‘parathyroid-kidney-intestine-bone’’ axis
include the parathyroid hormone (PTH), calcitriol and fibroblast
growth factor-23 (FGF-23), the roles of which are reviewed in detail
elsewhere.5,22,23
3.2. Nucleation of an amorphous mineral precursor
In humans, biologically derived mineral is formed by precipitation
in the presence of proteins and polysaccharides within the mild
physiological environment maintained at approximately pH 7.4
Fig. 3 Overview of the ‘‘parathyroid-kidney-intestine-bone’’ axis that regulates physiological phosphate levels. Ingested in food, phosphate is absorbed
through the intestines; that which is not absorbed is excreted in faeces. Phosphate is removed from the blood when bone is formed, and released when
bone is resorbed. As blood is filtered by the kidneys, any phosphate that is not reabsorbed is excreted in the urine. These mechanisms serve to keep
serum phosphate concentration constant.
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and near ambient temperature (37 1C).24 As H2PO4
 and
HPO4
2 ions are the most prominent orthophosphate species
present in physiological solution (Fig. 1), they likely play an
essential role in the early stages of biomineral formation. These
orthophosphate ions are able to react avidly with divalent
cations. Interaction with aqueous calcium ions for instance
results in the nucleation and subsequent growth of biologically
relevant mineral complexes, providing a chemical basis for
biomineralisation (Fig. 4A).
During the 1960s, an amorphous phase termed amorphous
calcium phosphate (Ca3(PO4)2nH2O, ACP) was first proposed as
a precursor to crystalline calcium orthophosphate minerals in
pseudo physiological systems.25 This includes HA, the major
mineral component of both human bone and teeth.26 The
presence of ACP in these tissues has since been confirmed
in vivo.27,28 ACP has also been identified in the hard tissues of
several other vertebrates29–31 and invertebrates,32,33 all but
confirming the universal importance of this precursor within
biomineralisation mechanisms across the animal kingdom.
ACP is comprised of spherical domains in the range of 0.7–1 nm
in diameter that agglomerate together to form particulates.34 Betts
and Posner first identified this nano-structuring during the 1970s
and so these domains have become better known as Posner’s
clusters35 (Fig. 4B). The standard formula of Posner’s clusters is
given as Ca9(PO4)6, correlating to a calcium to phosphorous
(Ca : P) ratio of 1.5, typical of ACP. The aggregation of
Posner’s clusters form spherical particles of ACP between
30–100 nm in diameter (Fig. 4C), which further aggregate into
chains prior to transforming toward a more stable phase.36–39
In the late 1990s, it was proposed that crystalline HA forms
via the step-wise assembly of Posner’s clusters.34 However,
speculation over the exact chemical composition of physiologically
derived clusters and the applicability of this model for in vivo
biomineral formation has only driven further eﬀorts to understand
the chemical structure of these early orthophosphate building
blocks. Advances in analytical methods have led to the proposition
that hydrated Posner’s clusters with the formula Ca9(PO4)6(H2O)30
are the structural building blocks of ACP. Further, in the early
stages of nucleation, these clusters may be calcium deficient,
contain protonated phosphate ion ligands and are charge
balanced by monovalent ions normally present in physiological
solution such as Na+ and Cl.40,41 Indeed, around 10–15% of the
orthophosphate within ACP produced in vitro from neutral
solution is protonated.42 Recently, computer simulations have
shed-light on the formation of non-idealised clusters in the
physiological environment rich in calcium and protonated
phosphate ion species.43 Cluster development in the presence
of HPO4
2 and H2PO4
 was shown to be enhanced by Na+ ions,
resulting in the generation of several varieties of calcium deficient
cluster complexes (including, but not limited to, [Ca7(H2PO4)-
(HPO4)5]
3+, [Ca3Na4(H2PO4)3(HPO4)3]
+ and [CaNa6(HPO4)6]
4) that
may aggregate through bridging phosphate ligands. Furthermore,
it was hypothesised that these non-idealised clusters evolve
through the ejection of protons, which in turn promotes association
with Ca2+ ions to counter balance changes in overall charge,
consequently increasing the Ca : P ratio toward 1.5. This is
consistent with the fact that protonated orthophosphate species
are present at the superficial surface of bone that is in contact
with physiological solution, whereas unprotonated Pi species
are prevalent in deep bone tissue.44,45 Taken together, the
formation of precursors to crystalline HA comprising of protonated
phosphate ions is seemingly consistent with the earliest nucleation
events both in vitro and in vivo.
3.3. Biological mineralisation and the formation of bone crystals
The template for bone mineralisation is osteoid, which is deposited
by osteoblasts. Osteoid is composed of bone’s organic components,
the major component being type-1 collagen. The exact role of this
phase in the infiltration of mineral precursors and the subsequent
evolution of highly oriented HA nanocrystals remains unknown,
however there are several hypotheses. There is evidence that NCPs
influence apatite nucleation, but also evidence that suggests that
nucleation sites exist at the terminus of collagen molecules. A
further body of evidence is growing to support the hypothesis that
orthophosphate mineral precursors are formed separately before
integrating with collagen.
Several potential sites of mineral association with collagen
fibrils have been identified.46 Mineralisation inhibitors, including
osteopontin (OPN), polyaspartic acid and fetuin, may stabilise ACP
as part of a net negatively charged complex, which can then interact
with collagen at sites that possess a net positive charge.47–50 The
mineral precursor may also exist in a fluidic state, referred to as
polymer-induced liquid-precursor (PILP), which can infiltrate the
supramolecular structure of collagen by capillary action before
solidifying and undergoing crystallisation.51
As bone formation progresses, the mineral content under-
goes a gradual transformation from amorphous to crystalline,
resulting in HA nanocrystals. Any remaining amorphous phase
Fig. 4 From orthophosphate ions to bone mineral. (A) Calcium and phosphate ions are colocalised in the physiological milieu. (B) Ions associate to form
Posner’s clusters (0.7–1 nm), with a Ca : P ratio of 1.5. (C) Posner’s clusters agglomerate to form ACP particulates (30–100 nm). (D) ACP transforms into a
crystalline HA phase with a Ca : P ratio of 1.67, which in bone possess a platelet morphology (50 nm  25 nm  3 nm). (E) In bone, the HA nanocrystals are
incorporated into collagen fibrils, mineralising the organic scaffold.
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may contribute toward maintaining ionic homeostasis. This
transformation has previously been spatially resolved bymapping
the transformation of ACP to mature mineral in zebrafish fin
rays.52 While the transformation of ACP to crystalline HA has
been proposed to proceed directly,53,54 there is also evidence to
support the involvement of several other calcium phosphate
phases. Acidic calcium orthophosphates, including dibasic calcium
phosphate dihydrate (CaHPO42H2O, DCPD, also known as
brushite) and octacalcium phosphate (Ca8(HPO4)2(PO4)45H2O,
OCP), have long been implicated as transient phases that evolve
from ACP prior to the formation of HA.55,56 The solubility
isotherms of calcium phosphates predict that the most stable
phase in physiological conditions is HA (logKsp at 25 1C =
116.8). This suggests that the evolution of less stable and more
soluble intermediate phases from ACP, such as highly soluble
DCPD (logKsp at 25 1C = 6.59) and metastable OCP (logKsp at
25 1C = 96.6), prior to the most thermodynamically favoured
composition of bone mineral, ensues through pathways that are
more kinetically favourable.57 Indeed, several in vitro systems
simulating pseudo physiological conditions have demonstrated
the transformation of highly soluble DCPD tometastable OCP,57–60
with OCP further shown to undergo transformation to physio-
logically stable HA.61–67 Phase transformations can reportedly
occur via various pathways, primarily hydrolysis and dissolution
followed by reprecipitation reactions. Whilst intermediate
phases remain difficult to detect during bone biomineralisation,
several recent studies have discovered the presence of beta-
tricalcium phosphate (b-Ca3(PO4)2, b-TCP), DCPD-like and OCP
phases in the early stages of in vivo bone formation, providing
some of the strongest evidence to date as to the crucial roles of
transient orthophosphate phases that are part of the biologically
mediated transformation of ACP to HA.68–71
Under correctly regulated conditions, biomineralisation
nearly always results in crystals that exhibit specific size, shape
and molecular organisation. Biological apatite crystals are
typically formed on the nanoscale. HA nanocrystals formed in
bone are described as platelets and are often assigned approximate
dimensions of 50 nm  25 nm  3 nm that align on the c-axis
parallel to the direction of collagen72 (Fig. 4D and E). It has been
proposed that OCP, which has a triclinic crystal structure
considered similar to that of bone mineral HA, may act as a
template during crystal growth.73 The precise dimensions and
organisation of bone HA crystals within a matrix of collagen,
together with other NCPs, results in the mechanical properties
of bone being greater than what would be expected given its
constituent elements. Bone has both high strength and toughness,
while its organic components are soft and ductile and inorganic
mineral is considerably stiﬀ and brittle.74–76
Biomacromolecules are believed to play crucial roles in
enacting spatial and temporal control over the formation of
mineral at the molecular scale. The precipitation of calcium
and orthophosphate ions from supersaturated solution in the
absence of biomacromolecules generally results in crystals of
considerable size. In the physiological environment, however,
nanocrystals may well be more kinetically stable whilst also
being of ideal size to form interactions with protein structures
and other physiological molecules. Bone possesses a suﬃcient
concentration of NCPs, many of which are phosphoproteins,
which may act to both control crystal growth and facilitate
interfacial interaction between collagen and HA.77 NCPs of the
small integrin-binding ligand N-glycosylation (SIBLING) family,
which includes OPN, bone sialoprotein (BSP), dentin matrix
protein 1 (DMP1), dentin sialophosphoprotein (DSPP) and matrix
extracellular phosphoglycoprotein (MEPE), have the capacity to
bind to collagen in a site-specific manner, as well as being able to
form interactions with or accumulate Ca2+ ions.78 NCPs not of the
SIBLING family include osteonectin (ON), osteocalcin (OC) and
bone-GLA protein. Taken together, these diﬀerent NCPs have been
implicated in playing a highly orchestrated role in biomineralisation
by means of promoting, inhibiting and regulating crystal
growth.79,80 OPN and OC have been shown to influence developing
HA crystals in vitro, however, the abundance of these proteins
in vivo may not be suﬃcient to interact with all nanocrystal
surfaces.81,82 Furthermore, OC has recently been found to complex
with OCP crystals in bone tissue, demonstrating the role of NCPs
in stabilising bone crystal nuclei during the embryonic stages of
formation.71,83 Although a typically overlookedmolecule for its role
in bone mineral formation, it has been proposed that citrate
(C6H5O7
3) may play a major role in stabilising crystal thickening
(up to 3 nm), whereas OC and OPNmay instead be responsible for
stabilising crystal lengthening (up to 50 nm).84
3.4. Biomineral composition
Pure stoichiometric HA (Ca10(PO4)6OH2) has a Ca : P ratio of 1.67.
However, the composition of biologically derived HA crystals
deviates widely from this ideal formula.85,86 In fact, pure stoichio-
metric HA is not known to form in biological systems.87 The
crystal lattice of HA can withstand substantial distortion to
accommodate naturally occurring ionic impurities, other than
calcium and orthophosphate, whilst maintaining overall charge
neutrality.88 For instance, approximately 20% of Ca2+ ions are
substituted with other cations, such as Mg2+ and Na+, both of
which are present in bone in minor concentrations.89 Other
cations, including Sr2+, Pb2+ and Zn2+, are also capable of filling
in lattice vacancies in place of Ca2+ but are only present within
bone in trace amounts.90 In the absence of Ca2+, vacant spaces
can remain unoccupied within the crystal unit cell, leading to
calcium deficient HA (Ca9(PO4)5(HPO4)OH).
91 However, carbo-
nate (CO3
2) is the most prevalent substitution in bone mineral.
Carbonate makes up between 2–8% of bone mineral by mass and
can take the place of either the hydroxyl groups (Ca10(PO4)6(OH)22x-
(CO3)x) or, more commonly, phosphate groups (Ca10x(PO4)6x-
(CO3)x(OH)2x), referred to as A- and B-type substitution,
respectively.92,93 Together, these substitutions heavily influence
the resulting chemistry of bone mineral in terms crystallinity,
thermodynamic stability, morphology, solubility and biological
properties.94–97
Typically, HA exhibits two crystallographic forms; a hexagonal
form that crystallises above 250 1C (P63/m space group with unit
cell parameters a = b = 9.432 Å, c = 6.881 Å) and a monoclinic
form that crystallises below 250 1C (P21/b space group with unit
cell parameters a = 9.421 Å, b = 2 Å, c = 6.881 Å, b = 1201).98,99
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Whilst impurities can cause the Ca : P ratio of biological mineral
to fall as low as 1.3, the combination of foreign ion inclusions,
ionic vacancies and Ca2+ deficiencies in fact contributes to
stabilising biological HA in the hexagonal crystal form.87 As well
as influencing crystal attributes on the atomic scale, impurities
are capable of enacting diﬀerences in the physical and chemical
attributes of biological mineral at greater length scales. This is
exemplified by the substitution of fluoride (F) into the HA lattice
resulting in fluorapatite (Ca10(PO4)6F2), which beneficially con-
tributes to making tooth mineral more resilient against acidic
conditions and demineralisation.100 An overview of the elemental
composition of mineralised tissues is provided in Table 1, high-
lighting the various proportions of trace elements found in bone,
enamel and dentine. Expectedly, elemental phosphorus is a
prominent component of each of these mineralised human
tissues (15.2–17.7%), predominantly found in the form of ortho-
phosphate. Whilst not a substituting component of the HA lattice,
normal mineralised tissue also contains a small proportion of PPi
(0.02–0.1%), which is important to normal bone formation and
function (Section 4.1).
4. The multiple roles of condensed
phosphates during biomineralisation
4.1. Pyrophosphate is both a regulator and promoter of
biomineralisation
Pyrophosphate (P2O7
4, PPi) has been identified as a potent
regulator of the formation of a wide variety of biominerals
in vivo. It has been most extensively studied in the context of
mineralised tissue formation, with respect to bones and teeth,
calcium oxalate deposition disorders such the formation of kidney
stones,103 vascular calcification104–106 and pseudoxanthoma elasti-
cum (PXE).107 To a lesser extent, PPi is implicated in joint chondro-
calcinosis and pseudogout syndrome, a rare condition whereby
crystals of calcium pyrophosphate dihydrate (Ca2P2O72H2O, CPPD)
are errantly formed in the synovial fluid of affected joints.108
In the context of calcium oxalate deposition, pyrophosphate
is known to act as a nucleation and crystal growth inhibitor.109
However, the inhibitory action of PPi has been shown to be primarily
due to Ca2+ complexation and surface interactions have only been
confirmed for the monohydrate phase (CaC2O4H2O).110,111 For
the deposition of calcium phosphate mineral, primarily HA, the
role of pyrophosphate is more complex as it acts as both a
source of orthophosphate and has been postulated to act as a
nucleation and growth inhibitor of HA through strong site
specific interactions.112 In PXE, chondrocalcinosis and pseudogout,
the PPi ion is directly involved in the precipitation of the mineral
phase, having been allowed to locally reach conditions of super-
saturation or through the lowering of barriers to nucleation.107,108
Whether all these eﬀects are purely chemical processes or act upon
biochemical pathways is a matter of debate. It is likely both
pathways are important and pyrophosphate species certainly
have a significant and critical role to play in the mineralisation
of hard tissues nonetheless.
Alkaline phosphatase (ALP) is an enzyme responsible for
dephosphorylating biomolecules. It is found in a wide range of
organisms with the same general function but in diﬀerent
structural forms to suit specific environments.113,114 In humans,
it is found in four forms, depending on its origin within the
body; intestinal, placental, placental-like, and liver/bone/kidney
(tissue-nonspecific alkaline phosphatase, TNAP).115 TNAP hydro-
lyses PPi and so is a key enzyme in the control of mineralisation.
TNAP plays a crucial role promoting mineralisation of the extra-
cellular matrix by restricting the concentration of PPi. Mutations in
the gene encoding TNAP cause hypophosphatasia, an inheritable
form of rickets and osteomalacia.116 PPi may be generated via the
cell drivenmetabolism of ATP to adenosinemonophosphate (AMP),
for example via nucleotide pyrophosphatase/phosphodiesterase 1
(NPP1), implicating ATP as a progenitor of bone mineralisation
inhibition.107,117 However, cleavage of PPi by TNAP generates
orthophosphate, whilst at the same time removing a proportion
of inhibitory species. Thus, PPi can act as both a local inhibitor
and source of orthophosphate to drive mineralisation.
As well as acting via inorganic pathways, PPi has been
demonstrated to influence biomolecular mineralisation path-
ways. For example, PPi has been shown to upregulate the NCP
osteopontin (OPN), found mainly in the bone matrix. OPN is
also present in other cell types, such as hypertrophic chondro-
cytes, odontoblasts, cementoblasts, macrophages, as well as
endothelial, smooth muscle and epithelial cells.118 As a potent
inhibitor of apatite formation, it shows a dose dependent
behaviour that is entirely depleted with removal of the phos-
phate group from OPN.81,119–121 The extended role of OPN with
relation to PPi in the regulation of bone mineralisation is
highlighted by two studies on mice unable to produce this
protein.122,123 In the neonatal period, the mice showed no
skeletal abnormalities; however, spleen cells were able to form
osteoclasts far more easily than wild type spleen cells, which only
became more pronounced with age. At the age of 4–6 months,
OPN deficient mice had twice the volume of trabecular bone and
three times the number of osteoclasts compared to wild type
mice. Additionally, OPN deficient mice were more resistant to
ovariectomy-induced bone resorption. Microcomputed tomo-
graphy analysis indicated a 60% reduction in bone volume by
Table 1 Composition of mineralised tissues and stoichiometric HA
(mass%)101,102
Enamel Dentine Bone HA
Calcium (Ca)a 36.5 35.1 34.5 39.6
Phosphorous (P)a 17.7 16.9 15.2 18.5
Sodium (Na)a 0.5 0.6 0.9 —
Magnesium (Mg)a 0.44 1.23 0.72 —
Potassium (K)a 0.08 0.05 0.03 —
Carbonate (CO3
2)b 3.5 5.6 7.4 —
Fluoride (F)a 0.01 0.06 0.03 —
Chloride (Cl)a 0.30 0.01 0.13 —
Pyrophosphate (P2O7
4)b 0.02 0.10 0.07 —
Total water (H2O)
b 1.5 10 10 —
Total organicb 1.5 20 25 —
Total inorganicb 97 70 65 100
Ca : P molar ratiob 1.63 1.61 1.71 1.67
a Ashed samples. b Non-ashed samples.
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ovariectomy in wild type mice, whereas the OPN deficient mice
exhibited only a 10% reduction in trabecular bone volume after
ovariectomy.
Studies have shown that TNAP activity increases in response
to PPi.120,124 Meanwhile it has been concluded that TNAP’s
primary function in mineralising tissues is to act together with
plasma cell membrane glycoprotein-1 to fine tune PPi con-
centrations to maintain steady-state levels and adequate con-
trol of mineralization.125 A further study has shown that OPN
represents a natural substrate for TNAP and therefore it may
regulate OPN function by dephosphorylation.126 As such it can be
seen that PPi forms a complicated feedback loop that contributes
to controlling biomineralisation in a number of ways.
4.2. The curious role of polyphosphates
Inorganic polyphosphates (polyP) are linear phosphate polymers.
These molecules have been implicated in the origin of life as non-
enzymatically produced energy carriers and phosphate donors,
and several distinct biological roles have been identified since
their discovery in cells in the late 19th century.17,18 PolyP is stored
intracellularly in what are commonly referred to as ‘dense
granules’, which are present in both prokaryotes and eukaryotes.
In mammals, polyP is particularly concentrated in the granules of
platelets; chains around 75 phosphate residues long are present
in platelets at a concentration of 1.1 mM, 10–20 fold higher than
inmajor organs.127 These granules also contain high concentrations
of divalent cations; polyP allows storage of high concentrations of
calcium and phosphate as an amorphous phase. The polyP in
platelets has been implicated in the clotting process, which is
particularly interesting for bone formation. Platelets are present in
the haematoma formed around sites of bone healing following
fracture, as well as the haematoma that develops prior to ectopic
bone formation. Platelet-rich plasma is commonly studied
pre-clinically, as well as currently used clinically, for repair of
bone defects.128
Dense polyP granules are found in many cell types, particularly
within the mitochondria. This includes osteoblasts, where polyP is
found in high concentrations (0.5 M in the dense granules in the
mitochondria), and osteoclasts, which have a high number of
mitochondria.129 These organelles have been implicated in bone
formation for some time, as large amounts of energy are required
both during bone formation and resorption.129
Biological reactions involving polyP can be grouped into two
categories: chain-lengthening and chain-shortening. Chain-
lengthening reactions are catalysed by the polyP kinase family
of enzymes. These enzymes can polymerise orthophosphate to form
polyP, or take phosphate residues from other molecules and add
them to the polyP chain, for example from ATP.130 Chain shortening
reactions are catalysed by several polyphosphatases, which can
cleave the chain in the middle (endopolyphosphatases), or cleave
the end phosphate (exophosphatases), which can then be attached
to another molecule such as ADP, or utilised as free orthopho-
sphate, such as in the formation of mineral.
The proposed role of polyP as a high-energy phosphate
donor is somewhat analogous to ATP; the same high-energy
(31 kJ mol1) phosphoanhydride bonds are present in both
molecules. Indeed, polyP has been shown to increase extra-
cellular ATP and ADP generation in SaOS-2 (osteoblast-like)
cells.131 In the same cell type, polyP was shown to promote
proliferation and mineralisation under hypoxic conditions, those
found in physiological and ectopic bone formation sites.132 This
suggests that polyP can act as an alternative phosphate and
metabolic energy source, particularly in extracellular or hypoxic
conditions, such as those in bone formation where ATP is not
readily available.133
In addition to its role as a substrate, polyP has also been
shown to have a direct influence on biomineralisation pathways
by inducing the expression of bone formation markers OPN, OC
and ALP, leading to the mineralisation of pre-osteoblast MC3T3
cells.105,134 Increased ALP expression has also been shown in
SaOS-2 cells, and an increase in intracellular calcium was seen
when calcium–polyP was used as a substrate, but not with Ca,
Pi, or polyP alone.135
As well as a role in bone formation, polyP has been shown to
increase cartilage production, but for a short time before it is
degraded by the polyphosphatases released by chondrocytes.136
This could enhance endochondral bone formation, by inducing
chondrocytes to express more cartilage tissue to act as the scaﬀold
for bone formation, then being degraded to halt cartilage production
while leaving behind the building blocks for mineralisation.
An integral role of polyP in bone remodelling has been
proposed.137 Firstly, osteoclasts use acids and enzymes to break
down bone, releasing calcium and orthophosphate ions. Enzymes
in the osteoclast then polymerise the orthophosphate into polyP.
The calcium–polyP complex is left behind by the osteoclast in the
bone resorption pit, or transferred through the extracellular space
either freely or in vesicle compartments to a previous resorption
pit. The calcium–polyP complex can then be used as a substrate by
osteoblasts to produce bone mineral.
This general idea outlines the importance of polyP as both a
substrate to be broken down, as well as a molecule capable of
preventing mineral formation, but in doing so facilitates high
concentrations of calcium and phosphate to coexist. However,
this mechanism is somewhat speculative. The enzymes associated
with osteoblasts, such as ALP, used to produce orthophosphate are
well researched,124,138 as are the enzymes and processes used by
osteoclasts to break down apatite and resorb bone.139 However,
polyphosphate kinases, the enzymes used to synthesise polyP,
have been mainly identified in bacteria. One of these enzymes
has also been found in Dictyostelium discoideum, a unicellular
eukaryote.140,141 Its conservation in eukaryotic cells suggests it may
also be present in mammals. Nevertheless, the enzyme has not
been found in mammalian cells to date, therefore the assumption
that such an enzyme exists in mammalian osteoclasts remains
unconfirmed.
This mechanism also fits with several current theories of bone
formation. Recently, in addition to ACP, amorphous calcium
carbonate (ACC) has been proposed as another pre-curser to bone
mineral.142,143 Osteoblasts could lay down this ACC phase, which
is then substituted for phosphate liberated from polyP. Further-
more, calcium–polyP may lead to the formation of ACP when
enzymatically degraded, which over time may form HA. Another
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theory suggests that the calcium–polyP complex could directly
infiltrate the collagen matrix by capillary action before being be
broken down in situ by osteoblast-secreted enzymes to form HA.
Alternatively, the polyP can be stored in and utilised by either
osteoblasts or vesicles.144
Condensed linear phosphates are becoming increasingly
recognised as multifunctional species with important physio-
logical roles. Most notable are the ability of phosphate polymers to
stimulate osteogenic markers, regulate the localised concentrations
of other phosphate species in a given biological microenvironment,
increase the levels of orthophosphate when broken down and
antagonise biological crystallisation processes (Fig. 5).
5. Conclusions and future perspectives
Together, various phosphate-based structures and molecules
play important roles in the formation and regulation of biological
mineral. Orthophosphate ions provide a building block for the
formation of bone mineral, whereas condensed phosphates have
the ability to both regulate mineral formation and provide a source
of additional orthophosphate as required. A comprehensive under-
standing of the complicated feedback loops involving phosphate
species is necessary for progression of research, particularly in the
area of regenerativemedicine. Challenges remain in the preparation
of synthetic forms of biological apatite mineral, thus investigating
the use of several phosphate species in mineral formation as occurs
in vivomay help to improve the clinical performance of bone-based
graftingmaterials. As well as biomineralisation, the wider utilisation
of phosphates throughout our bodies only adds to their complex
involvement in biochemical and chemical mechanisms essential to
the entirety of our bodily functions.
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